These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22422830)

  • 21. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Which patients should be evaluated for blood glucose variability?
    Candido R
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 2():9-12. PubMed ID: 24034514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
    Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
    Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive glucose lowering treatment in type 2 diabetes.
    Preiss D; Ray KK
    BMJ; 2011 Jul; 343():d4243. PubMed ID: 21791496
    [No Abstract]   [Full Text] [Related]  

  • 29. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
    Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
    Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between plasma adrenomedullin levels and metabolic control, risk factors, and diabetic microangiopathy in patients with type 2 diabetes.
    Turk HM; Buyukberber S; Sevinc A; Ak G; Ates M; Sari R; Savli H; Cigli A
    Diabetes Care; 2000 Jun; 23(6):864-7. PubMed ID: 10841017
    [No Abstract]   [Full Text] [Related]  

  • 31. Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?
    Ferguson LD; Sattar N
    Diabetes Obes Metab; 2013 May; 15(5):387-91. PubMed ID: 23020636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Glycaemic control and complications of diabetes: what about?].
    Bouhanick B; Barigou M; Kantambadouno JB; Chamontin B
    Presse Med; 2013 May; 42(5):849-54. PubMed ID: 23540378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
    Kautzky-Willer A; Kamyar MR; Gerhat D; Handisurya A; Stemer G; Hudson S; Luger A; Lemmens-Gruber R
    Gend Med; 2010 Dec; 7(6):571-83. PubMed ID: 21195357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Aggressive and early combined drug therapy. Antidiabetics for prevention of myocardial infarct].
    MMW Fortschr Med; 2003 Jun; 145(25):52. PubMed ID: 12891856
    [No Abstract]   [Full Text] [Related]  

  • 37. Importance of glycemic control.
    Shahady EJ
    J Fam Pract; 2011 Sep; 60(9 Suppl):S4-6. PubMed ID: 21912776
    [No Abstract]   [Full Text] [Related]  

  • 38. Tight glycaemic control and cardiovascular disease in type 2 diabetes.
    Demssie YN; Soran H; Younis N
    Br J Hosp Med (Lond); 2009 Jan; 70(1):31-2, 34. PubMed ID: 19357575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic inertia in type 2 diabetes: insights from the PANORAMA study in France.
    Simon D
    Diabetes Metab; 2012 Mar; 38 Suppl 3():S47-52. PubMed ID: 22541602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hypoglycemia and cardiovascular risk].
    Avogaro A
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.